Literature DB >> 27694491

Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Frances T Hakim1, Sarfraz Memon2, Ping Jin3, Matin M Imanguli2, Huan Wang3, Najibah Rehman2, Xiao-Yi Yan2, Jeremy Rose2, Jacqueline W Mays4, Susan Dhamala2, Veena Kapoor2, William Telford2, John Dickinson2, Sean Davis5, David Halverson2, Haley B Naik6, Kristin Baird7, Daniel Fowler2, David Stroncek3, Edward W Cowen6, Steven Z Pavletic2, Ronald E Gress2.   

Abstract

Although chronic graft-versus-host disease (CGVHD) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathogenesis is limited. To identify the main operant pathways across the spectrum of CGVHD, we analyzed gene expression in circulating monocytes, chosen as in situ systemic reporter cells. Microarrays identified two interrelated pathways: 1) IFN-inducible genes, and 2) innate receptors for cellular damage. Corroborating these with multiplex RNA quantitation, we found that multiple IFN-inducible genes (affecting lymphocyte trafficking, differentiation, and Ag presentation) were concurrently upregulated in CGVHD monocytes compared with normal subjects and non-CGVHD control patients. IFN-inducible chemokines were elevated in both lichenoid and sclerotic CGHVD plasma and were linked to CXCR3+ lymphocyte trafficking. Furthermore, the levels of the IFN-inducible genes CXCL10 and TNFSF13B (BAFF) were correlated at both the gene and the plasma levels, implicating IFN induction as a factor in elevated BAFF levels in CGVHD. In the second pathway, damage-/pathogen-associated molecular pattern receptor genes capable of inducing type I IFN were upregulated. Type I IFN-inducible MxA was expressed in proportion to CGVHD activity in skin, mucosa, and glands, and expression of TLR7 and DDX58 receptor genes correlated with upregulation of type I IFN-inducible genes in monocytes. Finally, in serial analyses after transplant, IFN-inducible and damage-response genes were upregulated in monocytes at CGVHD onset and declined upon therapy and resolution in both lichenoid and sclerotic CGVHD patients. This interlocking analysis of IFN-inducible genes, plasma analytes, and tissue immunohistochemistry strongly supports a unifying hypothesis of induction of IFN by innate response to cellular damage as a mechanism for initiation and persistence of CGVHD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27694491      PMCID: PMC5101132          DOI: 10.4049/jimmunol.1601054

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.

Authors:  Zoya Kuzmina; Verena Gounden; Lauren Curtis; Daniele Avila; Tiffani Taylor Rnp; Judy Baruffaldi; Edward W Cowen; Haley B Naik; Sarfaraz A Hasni; Jacqueline W Mays; Sandra Mitchell; Kristin Baird; Seth M Steinberg; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

2.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

3.  Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Authors:  Joanne E Croudace; Charlotte F Inman; Ben E Abbotts; Sandeep Nagra; Jane Nunnick; Prem Mahendra; Charles Craddock; Ram Malladi; Paul A H Moss
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

4.  FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.

Authors:  Paola Maderna; David C Cottell; Tiina Toivonen; Neil Dufton; Jesmond Dalli; Mauro Perretti; Catherine Godson
Journal:  FASEB J       Date:  2010-06-22       Impact factor: 5.191

5.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

6.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

7.  The incidence and risk factors for chronic graft-versus-host-disease.

Authors:  Jerzy Wojnar; Sebastian Giebel; Aleksandra Holowiecka-Goral; Małgorzata Krawczyk-Kulis; Miroslaw Markiewicz; Krzysztof Wozniczka; Jerzy Holowiecki
Journal:  Ann Transplant       Date:  2006       Impact factor: 1.530

8.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

9.  Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Authors:  Michelle Petri; Daniel J Wallace; Alberto Spindler; Vishala Chindalore; Kenneth Kalunian; Eduardo Mysler; C Michael Neuwelt; Gabriel Robbie; Wendy I White; Brandon W Higgs; Yihong Yao; Liangwei Wang; Dominique Ethgen; Warren Greth
Journal:  Arthritis Rheum       Date:  2013-04

10.  The Nlrp3 inflammasome regulates acute graft-versus-host disease.

Authors:  Dragana Jankovic; Jayanthi Ganesan; Michael Bscheider; Natalie Stickel; Felix C Weber; Greta Guarda; Marie Follo; Dietmar Pfeifer; Aubry Tardivel; Kristina Ludigs; Abdellatif Bouazzaoui; Katrin Kerl; Julius C Fischer; Tobias Haas; Annette Schmitt-Gräff; Anand Manoharan; Leonard Müller; Jürgen Finke; Stefan F Martin; Oliver Gorka; Christian Peschel; Jürgen Ruland; Marco Idzko; Justus Duyster; Ernst Holler; Lars E French; Hendrik Poeck; Emmanuel Contassot; Robert Zeiser
Journal:  J Exp Med       Date:  2013-08-26       Impact factor: 14.307

View more
  26 in total

Review 1.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 2.  Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant.

Authors:  Michael Byrne; Bipin Savani; Michael R Savona
Journal:  Ther Adv Hematol       Date:  2018-07-16

Review 3.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 4.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

5.  Possible roads to improve hemophagocytic lymphohistiocytosis outcome.

Authors:  Pietro Merli; Michael B Jordan; Franco Locatelli
Journal:  Blood Adv       Date:  2020-12-22

Review 6.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

7.  Biomarkers in chronic graft-versus-host disease: quo vadis?

Authors:  D Wolff; H Greinix; S J Lee; T Gooley; S Paczesny; S Pavletic; F Hakim; F Malard; M Jagasia; A Lawitschka; J A Hansen; D Pulanic; E Holler; A Dickinson; E Weissinger; M Edinger; S Sarantopoulos; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

Review 8.  Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.

Authors:  Sophie Paczesny
Journal:  Br J Haematol       Date:  2020-02-10       Impact factor: 6.998

9.  Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.

Authors:  Catherine Matte-Martone; Jinling Liu; Meng Zhou; Maria Chikina; Douglas R Green; John T Harty; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

10.  Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease.

Authors:  Sencer Goklemez; Filip Pirsl; Lauren M Curtis; Seth M Steinberg; Edward W Cowen; Jacqueline W Mays; Meg Kenyon; Judy Baruffaldi; Fran T Hakim; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.